Repatha's Heart Benefits Are Driving Labelling Changes

The "PCSK9 inhibitor" Repatha (evolocumab) labelling has that it has a new indication.

Repatha used to only be approved for lowering cholesterol in patients with certain genetic conditions.

But now it's approved for patients with cardiovascular (CV) disease to reduce their chance of having a heart attack or stroke.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote